Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neuropsychiatric disorders. Their focus is on leveraging the potential of their PDE10 inhibitors to treat symptoms related to schizophrenia. With a strong pipeline and promising results, Karuna Therapeutics is at the forefront of advancing treatment options for patients in need.
